WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered into an agreement to transition the manufacturing and development rights and remaining…Read More
Selecta Biosciences Inc Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL212 to Commercialization Partner Sobi
